Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

Canadian Cancer Trials Group CX.5 (GCIG: SHAPE) -- A Phase III Randomized Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk, Early-Stage Cervical Cancer

On behalf of the Study Chair, Dr. Marie Plante, the Canadian Cancer Trials Group is very pleased to announce that the CX.5 trial is centrally activated in Canada.

This trial was almost 3 years in the making and is the Group's first Canadian Cancer Trials Group-led trial for which it received a CIHR grant.

For more information about this trial, please contact Andrea Hiltz, CX.5 Study Coordinator, at 613-533-6430 or


Canadian Cancer Trials Group IND.213 -- A Randomized Phase II Study of Reolysin for Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy for Advanced/Metastatic Breast Cancer was centrally activated July 30, 2012.

Canadian Cancer Trials Group IND.194 -- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma -- was centrally activated July 24, 2012.